Spots Global Cancer Trial Database for Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients

Official Title: The Safety and Tolerance of Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in Subjects With Locally Advanced and Metastatic Pancreatic Adenocarcinoma: an Open, One-Armed, Single-Center, Phase Ⅱ Study.

Study ID: NCT05947825

Conditions

PDAC - Pancreatic Ductal Adenocarcinoma

Interventions

Combination of sitagliptin+ gemcitabine + nab-paclitaxel

Study Description

Brief Summary: The purpose of this study is to determine the safety and tolerance of sitagliptin combined with gemcitabine and albumin-bound paclitaxel in subjects with locally advanced and metastatic pancreatic ductal adenocarcinoma.

Detailed Description: This is a single-institution, prospective, open, one-armed phase Ⅱ clinical trial of sitagliptin combined with gemcitabine and nab-paclitaxel. This study will enroll 30 PDAC patients over 12-15 months.